- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05291091
Fas 2-studie av EDG-5506 i Beckers muskeldystrofi (CANYON)
En fas 2 randomiserad, dubbelblind, placebokontrollerad studie för att utvärdera effekten av EDG-5506 på säkerhet, biomarkörer, farmakokinetik och funktionella åtgärder hos vuxna och ungdomar med Beckers muskeldystrofi
A study of sevasemten (EDG-5506) in Becker muscular dystrophy (known as CANYON) and pivotal cohort (known as GRAND CANYON). The EDG-5506-201 CANYON study was expanded to include an additional 175 adult participants in a cohort called GRAND CANYON, that is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of sevasemten in adults with Becker.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The EDG-5506-201 protocol was amended to include an additional cohort thus consists of two parts.
Part 1: CANYON is a double-blind, randomized, placebo-controlled design to investigate the effect of sevasemten on the safety, pharmacokinetics, biomarkers, and functional measures. Approximately 32 adults and 18 adolescents with Becker muscular dystrophy are planned to enroll in this study. This study will have up to a 4-week Screening period, a 12-month Treatment period, followed by a 4-week follow-up period.
Approximately 32 adult participants will randomize to Cohort 1 or Cohort 2 in a 1:1 ratio then each cohort will further randomize to sevasemten or placebo in a 3:1 ratio.
Approximately 9 adolescent participants will enroll in Cohort 4 and randomize in a 2:1 ratio to sevasemten or placebo. Cohort 5 will randomize an additional 9 participants in a 2:1 ratio to either sevasemten or placebo after Cohort 4.
Part 2: GRAND CANYON or Cohort 6 is a double-blind, randomized, placebo-controlled design to investigate the safety and efficacy of sevasemten in adults with Becker muscular dystrophy after 18 months of treatment. Approximately 175 adults with Becker muscular dystrophy are planned to enroll in this study. This study will have up to a 4-week Screening period, an 18-month Treatment period, followed by a 4-week follow-up period.
Approximately 175 adult participants will be randomized in Cohort 6 in a 2:1 ratio either to sevasemten or placebo.
Enrollment for CANYON and GRAND CANYON has been completed.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
-
Fitzroy, Australien, VIC, 3065
- St Vincent's Hospital Melbourne
-
-
-
-
-
Leuven, Belgien
- Universitaire Ziekenhuizen Leuven
-
Liège, Belgien, 4000
- Centre Hospitalier Régional de la Citadelle
-
-
Belgium
-
Ghent, Belgium, Belgien, 9000
- University Hospital Gent
-
-
-
-
-
Copenhagen, Danmark
- Rigshospitalet
-
-
-
-
-
Marseille, Frankrike, 13005
- Centre de Reference des Maladies Neuromusculaires et de la SLA - AP-HM Hopital de La Timone
-
Nantes, Frankrike, 44093
- CHU de Nantes
-
Nice, Frankrike, 06001
- CHU de Nice - Hopital Pasteur 2 - Centre de reference des Maladies Neuromusculaires
-
Paris, Frankrike, 75013
- AP-HP Hopital Pitie-Salpetriere
-
-
-
-
Arkansas
-
Little Rock, Arkansas, Förenta staterna, 72202
- Arkansas Children's Hospital
-
-
California
-
La Jolla, California, Förenta staterna, 92037
- UC San Diego
-
Los Angeles, California, Förenta staterna, 90095
- UCLA Medical Center
-
Orange, California, Förenta staterna, 92868
- UC Irvine Medical Center
-
Palo Alto, California, Förenta staterna, 94304
- Stanford Neuroscience Health Center
-
Sacramento, California, Förenta staterna, 95817
- UC Davis Medical Center
-
-
Colorado
-
Aurora, Colorado, Förenta staterna, 80045
- UC Denver
-
-
Florida
-
Gainesville, Florida, Förenta staterna, 32611
- University of Florida
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30329
- Rare Disease Research
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60611
- Northwestern University
-
-
Indiana
-
Indianapolis, Indiana, Förenta staterna, 46202
- Indiana University School of Medicine
-
-
Iowa
-
Iowa City, Iowa, Förenta staterna, 52242
- University of Iowa
-
-
Kansas
-
Kansas City, Kansas, Förenta staterna, 66160
- University of Kansas Medical Center
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21205
- Kennedy Krieger Institute
-
-
Massachusetts
-
Worcester, Massachusetts, Förenta staterna, 01605
- University of Massachusetts Memorial Medical Center
-
-
Minnesota
-
Minneapolis, Minnesota, Förenta staterna, 55455
- University of Minnesota
-
-
Missouri
-
St Louis, Missouri, Förenta staterna, 63110
- Washington University School of Medicine
-
-
New York
-
Rochester, New York, Förenta staterna, 14642
- University of Rochester Medical Center
-
-
North Carolina
-
Hillsborough, North Carolina, Förenta staterna, 27278
- Rare Disease Research, LLC NC
-
-
Ohio
-
Cincinnati, Ohio, Förenta staterna, 45219
- University of Cincinnati Gardner Neuroscience Institute
-
Columbus, Ohio, Förenta staterna, 43205
- Nationwide Children's Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19104
- University of Pennsylvania
-
Pittsburgh, Pennsylvania, Förenta staterna, 15224
- University of Pittsburgh
-
-
Texas
-
Austin, Texas, Förenta staterna, 78759
- National Neuromuscular Research Institute
-
Denton, Texas, Förenta staterna, 76208
- Neurology Rare Disease Center
-
-
Virginia
-
Richmond, Virginia, Förenta staterna, 23298
- Virginia Commonwealth University Health
-
-
-
-
-
Jerusalem, Israel, 91240
- Hadassah University Hospital
-
Petah Tikva, Israel, 49202
- Schneider Children's Hospital of Israel
-
-
-
-
-
Milan, Italien, 20122
- Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico di Milano
-
Padova, Italien, 35128
- Azienda Ospedale - Università Padova
-
Rome, Italien, 00168
- Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
-
-
-
-
-
Leiden, Nederländerna, 2333 ZA
- Leids Universitair Medisch Centrum
-
-
-
-
-
Auckland, Nya Zeeland, 1010
- Optimal Clinical Trials
-
-
-
-
-
Barcelona, Spanien, 08035
- Hospital Universitario Vall d'Hebron
-
Barcelona, Spanien, 08907
- Hospital Universitari de Bellvitge
-
Donostia / San Sebastian, Spanien, 20014
- Hospital Universitario Donostia
-
Valencia, Spanien, 46026
- Hospital Universitari i Politecnic La Fe
-
-
-
-
-
London, Storbritannien, SW17 0QT
- St. George's University Hospitals NHS Foundation Trust
-
London, Storbritannien, NW1 2PG
- University College London Hospital
-
Newcastle, Storbritannien, NE7 7DN
- Newcastle Freeman Hospital
-
Salford, Storbritannien, M68HD
- Salford Royal Hospital
-
-
-
-
-
Munich, Tyskland, 80336
- Klinikum der Ludwig-Maximilians-Universitaet Muenchen
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
GRAND CANYON eligibility is listed below.
Key Inclusion Criteria:
- Adults (aged 18 to 50 years, inclusive) with a documented dystrophin mutation and phenotype consistent with Becker muscular dystrophy, and history of being ambulatory beyond 16 years of age without steroids; history of being ambulatory beyond 18 years of age with steroids.
- Able to complete the 100-meter timed test in < 200 seconds with or without use of mobility aid devices.
- Able to perform the North Star Ambulatory Assessment scale and achieve a score of 5 to 32, inclusive.
Key Exclusion Criteria:
- Medical history or clinically significant physical examination/laboratory result that, in the opinion of the investigator, would render the participant unsuitable for the study. This includes contraindications to magnetic resonance imaging such as non-compatible implanted medical devices or severe claustrophobia.
- Cardiac echocardiogram ejection fraction < 40%
- Forced vital capacity predicted <60% or using daytime ventilatory support
- Receipt of oral corticosteroids for the treatment of BMD in the previous 6 months.
- Receipt of an investigational drug within 30 days or 5 half-lives (whichever is longer) of the screening visit in the present study.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Adult Cohort 1
Drug: Sevasemten Drug: Placebo |
Sevasemten is administered orally once per day Placebo is administered orally once per day |
|
Experimentell: Adult Cohort 2
Drug: Sevasemten Drug: Placebo |
Sevasemten is administered orally once per day Placebo is administered orally once per day |
|
Experimentell: Adult Cohort 6
Drug: Sevasemten Drug: Placebo |
Sevasemten is administered orally once per day Placebo is administered orally once per day |
|
Experimentell: Adolescent Cohort 4
Drug: Sevasemten Drug: Placebo |
Placebo is administered orally once per day Sevasemten is administered orally once per day |
|
Experimentell: Adolescent Cohort 5
Drug: Sevasemten Drug: Placebo |
Placebo is administered orally once per day Sevasemten is administered orally once per day |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of treatment emergent adverse events in those treated with sevasemten or placebo
Tidsram: 12 months (CANYON Cohorts 1, 2, 4, 5), 18 months (GRAND CANYON Cohort 6)
|
All participants |
12 months (CANYON Cohorts 1, 2, 4, 5), 18 months (GRAND CANYON Cohort 6)
|
|
Severity of treatment emergent adverse events in those treated with sevasemten or placebo
Tidsram: 12 months (CANYON Cohorts 1, 2, 4, 5), 18 months (GRAND CANYON Cohort 6)
|
All participants |
12 months (CANYON Cohorts 1, 2, 4, 5), 18 months (GRAND CANYON Cohort 6)
|
|
Change from Baseline in serum Creatine Kinase
Tidsram: Averaged across Months 6, 9, 12 Months (CANYON Cohorts 1, 2)
|
Adult participants |
Averaged across Months 6, 9, 12 Months (CANYON Cohorts 1, 2)
|
|
Change from Baseline in total North Star Ambulatory Assessment score
Tidsram: 18 months (GRAND CANYON Cohort 6)
|
Adult participants |
18 months (GRAND CANYON Cohort 6)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change from Baseline in total North Star Ambulatory Assessment score
Tidsram: 12 Months (CANYON Cohorts 1, 2)
|
Adult participants |
12 Months (CANYON Cohorts 1, 2)
|
|
Pharmacokinetics as measured by steady state plasma concentration
Tidsram: 12 Months (CANYON Cohorts 1, 2, 4, 5), 18 months (GRAND CANYON Cohort 6)
|
All participants |
12 Months (CANYON Cohorts 1, 2, 4, 5), 18 months (GRAND CANYON Cohort 6)
|
|
Change from Baseline in growth as assessed by height centile on World Health Organization growth charts
Tidsram: 12 months (CANYON Cohorts 4, 5)
|
Adolescent participants |
12 months (CANYON Cohorts 4, 5)
|
|
Incidence of laboratory test-related treatment emergent adverse events
Tidsram: 18 months (GRAND CANYON Cohort 6)
|
Adult participants |
18 months (GRAND CANYON Cohort 6)
|
|
Change from Baseline in serum Creatine Kinase
Tidsram: 18 months (GRAND CANYON Cohort 6)
|
Adult participants |
18 months (GRAND CANYON Cohort 6)
|
|
Change from Baseline in plasma fast skeletal muscle Troponin I
Tidsram: Averaged across Months 6 and 12 (CANYON Cohorts 1, 2); 18 months (GRAND CANYON Cohort 6)
|
Adult participants |
Averaged across Months 6 and 12 (CANYON Cohorts 1, 2); 18 months (GRAND CANYON Cohort 6)
|
|
Change from Baseline in serum myoglobin
Tidsram: Averaged across Months 6, 9, and 12 (CANYON Cohorts 1,2); 18 months (GRAND CANYON Cohort 6)
|
Adult participants |
Averaged across Months 6, 9, and 12 (CANYON Cohorts 1,2); 18 months (GRAND CANYON Cohort 6)
|
|
Change from Baseline in total NSAD score (CANYON Cohorts 1,2)
Tidsram: 12 Months (CANYON Cohorts 1, 2)
|
Adult participants |
12 Months (CANYON Cohorts 1, 2)
|
|
Change from Baseline in 4-stair climb test
Tidsram: 18 months (GRAND CANYON Cohort 6)
|
Adult participants |
18 months (GRAND CANYON Cohort 6)
|
|
Change from Baseline in the 10-meter walk/run test
Tidsram: 12 Months (CANYON Cohorts 1, 2), 18 Months (GRAND CANYON Cohort 6)
|
Adult participants |
12 Months (CANYON Cohorts 1, 2), 18 Months (GRAND CANYON Cohort 6)
|
|
Change from Baseline in 100-meter timed test
Tidsram: 12 Months (CANYON Cohorts 1, 2), 18 Months (GRAND CANYON Cohort 6)
|
Adult participants |
12 Months (CANYON Cohorts 1, 2), 18 Months (GRAND CANYON Cohort 6)
|
|
Change from Baseline in stride velocity (95th percentile)
Tidsram: 18 Months (GRAND CANYON Cohort 6)
|
Adult participants |
18 Months (GRAND CANYON Cohort 6)
|
|
Month 18 change from Baseline in fat fraction of upper leg muscles as assessed by Magnetic Resonance Imaging
Tidsram: 18 months (GRAND CANYON Cohort 6)
|
Adult participants |
18 months (GRAND CANYON Cohort 6)
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studiestol: Joanne Donovan, MD, PhD, Edgewise Therapeutics, Inc.
- Studiestol: Roxana D. Dreghici, Edgewise Therapeutics, Inc.
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- EDG-5506-201
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .